2020 POSTER PRESENTATIONS
P01: Appoptotic Induced Properties and Colon Cancer Inhibitory Activity of Some New Promising Indole Derivatives Structurally Related to Indomethacin, Presented by Sally E., Al-Azhar University
P02: New Cyanopyridine-Based Scaffold as PIM-1 Inhibitors and Apoptotic Inducers: Synthesis and SARs Study, Presented by Amel F., Al-Azhar University
P03: LinearDesign: Efficient Algorithms for Optimized mRNA Sequence Design, Presented by He Z., Baidu USA LLC
P04: Fast "Linkerology" Support for PROTACS Design, Presented by Marcus G., BioSolveIT GmbH
P05: SAR by Space: Enriching BRD4 Inhibitor Hit Sets from the Chemical Space, Presented by Franca-M. K., BioSolveIT GmbH
P06: The Big Data in Drug Discovery: Artificial Intelligence and the CSD, Presented by Vera P., Cambridge Crystallographic Data Centre, Inc.
P07: Molecular and Functional Study of the PTK7 Tyrosine Kinase Receptor and Targeting in Colorectal Cancer, Presented by Laetitia G., Centre de Recherche en Cancerologie de Marseille (CRCM)
P08: Exploiting the Biophysical Sweet Spot in Fragment-Based Drug Discovery, Presented by Thomas P., Concept Life Sciences
P09: Structure-Based Design Generated Novel Hydroxamic Acid Based Preferential HDAC6 Lead Inhibitor with On-Target Cytotoxic Activity Against Primary Choroid Plexus Carcinoma, Presented by Shaymaa K., Damanhour University
P10: Peptiligase Technology Platform, Presented by Leendert V., EnzyTag B.V.
P11: NMR2 as a Fast NMR Method for Structure Activity Relationship Investigation and Further Structure-Based Drug Design, Presented by Felix T., ETH Zurich
P12: Detection of Endogenous Protein Turnover Induced by Targeted Degraders, Presented by Chao-Tsung Y., Eurofins Discovery
P13: E3scan™ Ligand Binding Assay Platform for Targeted Protein Degradation and PROTAC Discovery, Presented by Ksenya C., Eurofins Discovery
P14: Parallel Solid Phase Synthesis Optimization of Antimicrobial Peptide LL-37: Effects of Resins in Peptide Purity, Presented by Cyf R., Gyros Protein Technologies
P15: F2X-Universal and F2X-Entry: Structurally Diverse Compound Libraries for Crystallographic Fragment Screening, Presented by Jan W., Helmholtz-Zentrum Berlin
P16: Employing Multiple Tools to Solve Challenging Metabolite Projects, Presented by Liam E., Hypha Discovery Ltd.
P17: Composition of the F2X-Universal and F2X-Entry Fragment Libraries, Presented by Alexander M., Idorsia Pharmaceuticals Ltd.
P18: Novel Fragment Libraries from Life Chemicals, Presented by George B., Life Chemicals, Inc.
P19: Screening Compound Libraries for HTS and Lead Discovery Projects, Presented by George B., Life Chemicals, Inc.
P20: PPI and Epigenetic Targeted Libraries from Life Chemicals, Presented by Vasily P., Life Chemicals, Inc.
P21: Synergistic Use of Biophysical Techniques for the Characterization of a Novel ATP-Cone Driven Activity Regulation of Ribonucleotide Reductase, Presented by Muneera B., Malvern Panalytical, Inc.
P22: Analysis of Commercial and Public Compound Databases by Self-Organizing Maps, Presented by Greg P., Mcule
P23: Conformation, Permeability and Permeation Mechanism of Cyclic Hexapeptide Diastereomers, Presented by Satoshi O., Mitsubishi Tanabe Pharma Corporation
P24: Identification of Novel Binding Sites by High-Concentration NMR and X-Ray Crystallography, Presented by Rebecca W., Monash University
P25: Identification of Selective Covalent Fragment Inhibitors from Parallel Reaction Mixtures, Presented by Rebecca W., Monash University
P26: Regulation of miRNA by Synthetic Small Cyclic Molecule in Cancer, Presented by Sanjukta M., National Centre for Biological Sciences
P27: Single Atom Changes in Newly Synthesized HIV Protease Inhibitors Reveal Structural Basis for Extreme Affinity, High Genetic Barrier, and Adaptation to the HIV Protease Plasticity, Presented by Haydar B., National Institutes of Health, National Cancer Institute
P28: A Novel Method for the Early, Rapid Assessment of Tissue Distribution for New Drug Candidates, Presented by Jon B., Pharmaron UK
P29: A Simple Homogeneous Bioluminescent Immunoassay to Interrogate Cellular Signaling Pathway Regulation, Presented by Brian H., Promega Corporation
P30: Cellular Kinase Assays that Deliver Quantitative Compound Affinity, Occupancy, and Selectivity in Live Cells Using NanoBRET, Presented by Kristin H., Promega Corporation
P31: NanoBRET in Live Cells as a Method to Assess E3 Ligase and Target Protein Occupancy for PROTACs, Presented by Kara M., Promega Corporation
P32: Real-Time Monitoring of PROTAC and Molecular Glue Targeted Degradation in Living Cells, Presented by Steven E., Promega Corporation
P33: Medicinal Chemistry Optimization of a High-Throughput Screening (HTS) Hit for Mesenchymal Cancers, Presented by Francisco M., Scripps Research Institute
P34: PRESTO-Tango Screening Reveals Gut Microbial Metabolites that Modulate Host Physiology, Presented by Phu Khat N., Yale University
P35: Druggability of the Protein Interactome: High-Throughput Discovery of Chemical Modulators of Protein-Protein Interactions, Presented by Soon Gang C., Dana-Farber Cancer Institute